Diverse associations between ESR1 polymorphism and breast cancer development and progression

Clinical Cancer Research

Volumn 16, Issue 13, 2010, Pages 3473-3484

  Ding, Shian Ling ^a   Yu, Jyh Cherng ^b   Chen, Shou Tung ^d   Hsu, Giu Cheng ^b   Hsu, Huan Ming ^b   Ho, Jar Yi ^b   Lin, Yu Hsin ^c   Chang, Chien Ching ^c   Fann, Cathy S J ^c   Cheng, Chun Wen ^e   Wu, Pei Ei ^c   Shen, Chen Yang ^c,f  

^a Kang Ning Junior College of Medical Care and Management   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA POLYMORPHISM; ESR1 GENE; FEMALE; GENE; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77954224238     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3092     Document Type: Article

References (52)

1. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47.
2. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16. (Pubitemid 34498648)
3. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-12. (Pubitemid 37328797)
4. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
5. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35. (Pubitemid 23269068)
6. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-22.
7. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631-43.
8. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44.
9. Osborne CK, Schiff R, Fuqua SA, et al. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001;7:4338-42s.
10. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
11. Pearce ST, Jordan VC. The biological role of estrogen receptors α and β in cancer. Crit Rev Oncol Hematol 2004;50:3-22.
12. Welboren WJ, Stunnenberg HG, Sweep FC, et al. Identifying estrogen receptor target genes. Mol Oncol 2007;1:138-43.
13. Safe S, Kim K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 2008;41:263-75.
14. Kahn SA, Rogers MA, Khurana KK, et al. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998;90:37-42. (Pubitemid 28078079)
15. Ali SH, O'Donnell AL, Balu D, et al. Estrogen receptor-α in the inhibition of cancer growth and angiogenesis. Cancer Res 2000;60:7094-8. (Pubitemid 32059189)
16. Osborne CK, Zhao H, Fuqua SAW. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18:3172-86.
17. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
18. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007;25:5815-24.
19. Menasce LP, White GR, Harrison CJ, et al. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 1993;17:263-5.
20. Zheng W, Long J, Gao YT, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 2009;41:324-8.
21. Cai Q, Shu XO, Jin F, et al. Genetic polymorphisms in the estrogen receptor á gene and risk of breast cancer: results from the Shanghai breast cancer study. Cancer Epidemiol Biomarkers Prev 2003;12:853-9.
22. Modugno F, Zmuda JM, Potter D, et al. Association of estrogen receptor a polymorphisms with breast cancer risk in older Caucasian women. Int J Cancer 2005;116:984-91.
23. Conway K, Parrish E, Edmiston SN, et al. The estrogen receptor-á A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res 2005;7:R871-80.
24. Colson NJ, Lea RA, Quinlan S, et al. No role for estrogen receptor 1 gene intron 1 Pvu II and exon 4 C325G polymorphisms in migraine susceptibility. BMC Med Genet 2006;7:12.
25. Mavaddat N, Dunning AM, Ponder BAJ, et al. Common genetic variation in candidate genes and susceptibility to sub-types of breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:255-9.
26. Dunning AM, Healey CS, Baynes C, et al. Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 2009;18:1131-9.
27. Bernstein L, Yuan JM, Ross RK, et al. Serum hormone levels in premenopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies. Cancer Causes Control 1990;1:51-8.
28. Shen CY, Yu JC, Lo YL, et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 2000;60:3884-92.
29. Ding SL, Yu JC, Chen ST, et al. Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility. Carcinogenesis 2009;30:43-9.
30. Ding SL, Sheu LF, Yu JC, et al. Abnormality of the DNA doublestrand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumor grade. Br J Cancer 2004;90:1995-2001.
31. Ding SL, Yu JC, Chen ST, et al. Genetic variation in the premature aging gene WRN: a case-control study on breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2007;16:263-9.
32. Yu JC, Ding SL, Chang CH, et al. Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell-cycle and ubiquitin ligase genes. Carcinogenesis 2009;30:1562-70.
33. Le Doussal V, Tubiana-Hulin M, Friedman S, et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989;64:1914-21.
34. Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, Morrow M, editors. AJCC cancer staging manual. 6. Philadelphia: Springer; 2002.
35. Pan WH, Fann CSJ, Wu JY, et al. Han Chinese Cell and Genome Bank in Taiwan: purpose, design and ethical considerations. Hum Hered 2006;61:27-30.
36. Sellers TA. Genetic ancestry and molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2004;13:499-500.
37. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
38. Dempster AP, Laird NM, Rubin D. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc B 1977;39:1-38.
39. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
40. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
41. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
42. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
43. Yang HC, Lin CH, Hsu CL, et al. A comparison of major histocompatibility complex SNPs in Han Chinese residing in Taiwan and Caucasians. J Biomed Sci 2006;13:489-98.
44. Yaich L, Dupont WD, Cavener DR, et al. Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res 1992;52:77-83.
45. Shin A, Kang D, Nishio H, et al. Estrogen receptor á gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 2003;80:127-31.
46. Spivack SD, Hurteau GJ, Fasco MJ, et al. Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin Cancer Res 2003;9:6002-11.
47. Fearon ER. Connecting estrogen receptor function, transcriptional repression, and E-cadherin expression in breast cancer. Cancer Cell 2003;3:307-10.
48. Fujita N, Jaye DL, Kajita M, et al. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003;113:207-19. (Pubitemid 36514972)
49. Oka H, Shiozaki H, Kobayashi K, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993;53:1696-701.
50. Helguero LA, Lindberg K, Gardmo C, et al. Different roles of estrogen receptors á and â in the regulation of E-cadherin protein levels in a mouse mammary epithelial cell line. Cancer Res 2008;68:8695-704.
51. Cardamone MD, Bardella C, Gutierrez A, et al. ERá as ligand-ndependent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proc Natl Acad Sci U S A 2009;106:7420-5.
52. Bracke ME, Charlier C, Bruyneel EA, et al. Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype. Cancer Res 1994;54:4607-9.